Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02703493 · ClinicalTrials.gov registry record · NA

Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer

A NA study, sponsored by Northwell Health.

Completed
Registry status
NA
Development phase
39
Enrollment target

NCT02703493: Completed NA study, sponsored by Northwell Health.

NCT02703493 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02703493, a NA study, has completed, sponsored by Northwell Health.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target

Study Summary

This is a Phase I study looking to evaluate the safety of dose escalated stereotactic radiotherapy (SRS) without exceeding the maximum tolerated dose in patients with high-risk human papilloma virus (HPV)- unassociated oropharyngeal squamous cancer.

Primary Outcome

study completed.

Interventions

  • RADIATION Stereotactic Radiosurgery

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2010-03-01
Est. Completion 2022-12-31
Phase NA
Northwell Health

370 total trials

What the finished NCT02703493 record still lists

NCT02703493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Stereotactic Radiosurgery is the first listed.

NCT02703493 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02703493 about?

NCT02703493 is a clinical study titled "Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer". This is a Phase I study looking to evaluate the safety of dose escalated stereotactic radiotherapy (SRS) without exceeding the maximum tolerated dose in patients with high-risk human papilloma virus (HPV)- unassociated oropharyngeal squamous cancer.

What is the current status of trial NCT02703493?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2010-03-01. Estimated completion is 2022-12-31.

What interventions are being tested in trial NCT02703493?

The interventions under investigation include: Stereotactic Radiosurgery (RADIATION).

Who is sponsoring clinical trial NCT02703493?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02703493's enrollment target sits among peer trials

39 1536th of 2000 higher than 463 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02703493, the US trial registry maintained by the National Library of Medicine. NCT02703493 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.